ERBB2 and breast carcinoma: Based on this study above, Cheema et al. [75] examined and compared the efficacy, adhesive targeting, and drug specificity of emodin delivered via SF-ELP versus ELP, against breast cancer cells that over-express the Her2/neu proto-oncogene.